IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. (vol 67, pg 1516, 2008)

被引：0
|
作者：
Emery, P.
Keystone, E.
Tony, H. P.
Cantagrel, A.
van Vollenhoven, R.
Sanchez, A.
机构：
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2009年 / 68卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：296 / 296
页数：1
相关论文
共 6 条
  • [1] IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
    Emery, P.
    Keystone, E.
    Tony, H. P.
    Cantagrel, A.
    van Vollenhoven, R.
    Sanchez, A.
    Alecock, E.
    Lee, J.
    Kremer, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) : 1516 - 1523
  • [2] Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
    Strand, Vibeke
    Burmester, Gerd R.
    Ogale, Sarika
    Devenport, Jenny
    John, Ani
    Emery, Paul
    RHEUMATOLOGY, 2012, 51 (10) : 1860 - 1869
  • [3] Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. (vol 374, pg 210, 2009)
    Smolen, J. S.
    Kay, J.
    Doyle, M. K.
    LANCET, 2009, 374 (9699): : 1422 - 1422
  • [4] Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
    Nash, Peter
    Kirkham, Bruce
    Okada, Masato
    Rahman, Proton
    Combe, Benard
    Burmester, Gerd-Ruediger
    Adams, David H.
    Kerr, Lisa
    Lee, Chin
    Shuler, Catherine L.
    Genovese, Mark
    LANCET, 2017, 389 (10086): : 2317 - 2327
  • [5] IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study
    Juhl, Pernille
    Thudium, Christian Schneider
    Gudmann, Natasja Staehr
    Karsdal, Morten Asser
    Bay-Jensen, Anne-Christine
    Siebuhr, Anne Sofie
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 568 - 574
  • [6] Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
    Ritchlin, Christopher
    Rahman, Proton
    Kavanaugh, Arthur
    McInnes, Iain B.
    Puig, Lluis
    Li, Shu
    Wang, Yuhua
    Shen, Yaung-Kaung
    Doyle, Mittie K.
    Mendelsohn, Alan M.
    Gottlieb, Alice B.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (06) : 990 - 999
1